BRA
CVS icon

Biechele Royce Advisors’s CVS Health CVS Stock Holding History

Biechele Royce Advisors’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$17.1M Sell
271,413
-2,933
-1% -$171K 5.63% 6
2024
Q2 		$16.2M Buy
274,346
+71,546
+35% +$4.48M 5.47% 5
2024
Q1 		$16.2M Buy
202,800
+3,513
+2% +$268K 5.36% 5
2023
Q4 		$15.7M Buy
199,287
+7,018
+4% +$499K 5.15% 6
2023
Q3 		$13.4M Buy
192,269
+6,232
+3% +$442K 4.95% 6
2023
Q2 		$12.9M Buy
186,037
+25,508
+16% +$1.81M 4.48% 9
2023
Q1 		$11.9M Buy
160,529
+11,864
+8% +$995K 4.44% 8
2022
Q4 		$13.9M Buy
148,665
+1,168
+0.8% +$113K 5.65% 4
2022
Q3 		$14.1M Sell
147,497
-1,405
-0.9% -$139K 6.62% 2
2022
Q2 		$13.8M Sell
148,902
-309
-0.2% -$30.2K 6.13% 3
2022
Q1 		$15.1M Sell
149,211
-2,956
-2% -$311K 6.02% 3
2021
Q4 		$15.7M Buy
152,167
+789
+0.5% +$72.9K 6.28% 3
2021
Q3 		$12.8M Buy
151,378
+10,414
+7% +$872K 5.68% 3
2021
Q2 		$11.8M Buy
140,964
+7,693
+6% +$630K 5.09% 4
2021
Q1 		$10M Buy
133,271
+2,017
+2% +$147K 5.05% 5
2020
Q4 		$8.96M Buy
131,254
+2,907
+2% +$189K 5.05% 6
2020
Q3 		$7.5M Sell
128,347
-3,900
-3% -$243K 4.71% 8
2020
Q2 		$8.59M Sell
132,247
-1,445
-1% -$91K 5.42% 5
2020
Q1 		$7.93M Sell
133,692
-1,137
-0.8% -$75.9K 6.1% 3
2019
Q4 		$10M Sell
134,829
-3,533
-3% -$248K 6.02% 5
2019
Q3 		$8.73M Sell
138,362
-10,924
-7% -$647K 5.77% 4
2019
Q2 		$8.13M Buy
149,286
+32,379
+28% +$1.74M 5.37% 6
2019
Q1 		$6.3M Buy
116,907
+6,520
+6% +$402K 4.08% 9
2018
Q4 		$7.23M Buy
110,387
+3,365
+3% +$251K 5.2% 4
2018
Q3 		$8.43M Sell
107,022
-249
-0.2% -$17.8K 5.27% 4
2018
Q2 		$6.9M Buy
107,271
+17,362
+19% +$1.14M 4.63% 3
2018
Q1 		$5.59M Buy
89,909
+3,903
+5% +$280K 3.9% 9
2017
Q4 		$6.24M Buy
+86,006
New +$6.25M 4.24% 7

Other funds holding CVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Biechele Royce Advisors's CVS Position: Q3 2024 in Review

Biechele Royce Advisors reduced its CVS Health (CVS) stake by 1.1% in Q3 2024, selling an estimated $171K and leaving 271,413 shares worth $17.1M. The position accounts for 5.63% of the portfolio, ranked #6.

Biechele Royce Advisors first reported a position in CVS in Q4 2017 and has held it in 28 quarters since. 1,841 funds tracked by Wall St. Rank hold CVS as of Q3 2024.

  • Biechele Royce Advisors held 271,413 shares of CVS Health worth $17.1M as of Q3 2024.
  • Biechele Royce Advisors sold 2,933 CVS Health shares in Q3 2024, an estimated $171K.
  • CVS Health made up 5.63% of Biechele Royce Advisors's portfolio in Q3 2024, its #6 holding.
  • Biechele Royce Advisors first reported a position in CVS Health in Q4 2017 and has held it in 28 quarters since.
  • 1,841 funds tracked by Wall St. Rank held CVS Health as of Q3 2024.

Based on Biechele Royce Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.